Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Miramistin Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5481757 | 1.00 | MEN1 (0.63) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5164193 | 1.00 | MEN1 (0.63) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Miramistin Ion SCHEMBL17530472 | 0.99 | MEN1 (0.64) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL11305761 | 0.99 | DNM1 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL10034064 | 0.99 | DNM1 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Miramistin Ion SCHEMBL2238282 | 0.99 | DNM1 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Miramistin Ion SCHEMBL23922700 | 0.97 | MEN1 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28383398 | 0.93 | EPHX2 (0.65) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL7091153 | 0.92 | EPHX2 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 | |
| SCHEMBL7089077 | 0.92 | EPHX2 (0.62) | MEN1KMT2ATP53MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078012-A1 | NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE | VERTELOVA REGINA (US) | 2026-03-19 | — | — | US | claimed |
| US-12515963-B2 | Nanoparticle composition and method of inhibiting ovarian cancer cell viability | VERTELOVA REGINA (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025034143-A1 | PHARMACEUTICAL COMPOSITION OF GRAMICIDIN S FOR TREATING INFECTIOUS INFLAMMATORY DISEASES OF THE ORAL CAVITY AND THROAT | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2025-02-13 | — | — | WO | claimed |
| US-12194147-B2 | Hydrophilic/hydrophobic pharmaceutical composition and method of its production and use | PATHELEN HEALTH CARE AG (CH) | 2025-01-14 | — | — | US | claimed |
| US-20220250932-A1 | METHOD OF TREATING CANCER WITH A METALLIC NANOPARTICLE COMPOSITION | VERTELOVA REGINA (US) | 2022-08-11 | — | — | US | claimed |
| US-11286171-B2 | Therapeutic metallic nanoparticle composition and method of use and manufacture thereof | VERTELOVA REGINA (US) | 2022-03-29 | — | — | US | claimed |
| EP-3585422-B1 | ANTISEPTIC COMPOSITION COMPRISING UNITHIOL AND DIMETHYLSULFOXIDE, USE OF THE COMPOSITION AND METHOD OF WOUND TREATMENT WITH ITS USE | MEDID INNOVATION DEV LTD (CY) | 2022-02-09 | — | — | EP | claimed |
| EP-3585399-B1 | ANTISEPTIC COMPOSITION COMPRISING POLYVINYLPYRROLIDONE AND UNITHIOL AND USE OF THE COMPOSITION | MEDID INNOVATION DEV LTD (CY) | 2022-02-09 | — | — | EP | claimed |
| WO-2021087419-A1 | NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE | VERTELOVA REGINA (US) | 2021-05-06 | — | — | WO | claimed |
| US-20210130182-A1 | NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE | VERTELOVA REGINA (US) | 2021-05-06 | — | — | US | claimed |
| EP-2990034-A1 | ANTISEPTIC VETERINARY FORMULATION AND METHODS FOR USE THEREOF | Obshchestvo S Ogranichennoy Otvetstvennostyu "Nanobiotekh" (RU) | 2016-03-02 | — | — | EP | claimed |
| EP-2536400-B1 | MEDICAMENT COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (AT) | 2014-09-24 | — | — | EP | claimed |
| EP-2536400-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | Megainpharm GmbH (AT) | 2012-12-26 | — | — | EP | claimed |
| WO-2011101113-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (AT) | 2011-08-25 | — | — | WO | claimed |
| WO-2011100994-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (DE) | 2011-08-25 | — | — | WO | claimed |
| US-20260078012-A1 | NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE | VERTELOVA REGINA (US) | 2026-03-19 | — | — | US | disclosed |
| US-12515963-B2 | Nanoparticle composition and method of inhibiting ovarian cancer cell viability | VERTELOVA REGINA (US) | 2026-01-06 | — | — | US | disclosed |
| CN-101100432-B | Method for synthesizing benzyldimethyl[3-(myristamide)propyl]ammonium chloride | INST PHARM & TOXICOLOGY AMMS | 2010-08-04 | — | — | CN | disclosed |
| CN-101100432-A | Method for synthesizing benzyldimethyl[3-(myristamide)propyl]ammonium chloride | INST PHARM & TOXICOLOGY AMMS (CN) | 2008-01-09 | — | — | CN | disclosed |
| WO-1993000892-A1 | PHARMACEUTICAL PREPARATION | KRIVOSHEIN JURY SEMENOVICH (UA) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078012-A1 | NANOPARTICLE COMPOSITION AND METHOD OF USE AND MANUFACTURE | SLC11A2, MCL1, PRF1 | MEN1 704/4885KMT2A 4749/4885TP53 25/4885 |
| US-12194147-B2 | Hydrophilic/hydrophobic pharmaceutical composition and method of its production and use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SPECC1L, ABCG2 | MEN1 1419/4885KMT2A 4410/4885TP53 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.